DLBCL stands for diffuse large B-cell lymphoma, an aggressive subtype of non-Hodgkin lymphoma and the most common NHL subtype in the United States. It typically grows rapidly but can respond well to appropriate systemic treatment. Clinical management often includes immunochemotherapy.
Epcoritamab plus lenalidomide cut progression risk by 60% in R/R DLBCL in a phase 3 trial. Five-year AUGMENT follow-up supports R2 in indolent NHL; a phase 2 penpulimab-lenalidomide-R-GemOx trial showed activity in DLBCL.
Real-world studies show early complete response after CAR T-cell therapy predicts sustained remission in large B-cell lymphoma, while historical chemotherapy yields poor outcomes in high-risk patients. Data from registries highlight a significant event-free survival advantage for second-line axicabtagene ciloleucel versus standard-of-care salvage therapy.
A phase 1 trial shows denileukin diftitox administered before CAR-T therapy has a favorable safety profile and encouraging efficacy in high-risk DLBCL patients, with an 86% overall response rate and 77% one-year progression-free survival. The treatment demonstrated consistent regulatory T-cell depletion, supporting its immunomodulatory mechanism. Larger controlled studies are needed to confirm these preliminary findings.
Incyte executives presented a post-Jakafi growth strategy at the Barclays conference, outlining four product launches and pipeline progress in hematology, immunology, and solid tumors ahead of Jakafi's loss of exclusivity in 2029.
Metabolic pathway scores consistently distinguished patients who developed severe neurologic events after CAR T-cell therapy across six clinical trials, surpassing traditional inflammatory markers in predictive performance.
Citius Pharmaceuticals reported $3.9 million in first revenue from LYMPHIR's December 2025 launch for cutaneous T-cell lymphoma, while subsidiary Citius Oncology announced positive Phase 1 data showing 86% response rate when LYMPHIR was administered prior to CAR-T therapy in high-risk lymphoma patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774299 |
Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL |
NOT_YET_RECRUITING | PHASE2 |
| NCT07709624 |
Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study |
ACTIVE_NOT_RECRUITING | |
| NCT07643805 |
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07570017 |
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07498920 |
Gut Microbiome in DLBCL Treated With Glofitamab |
NOT_YET_RECRUITING | |
| NCT07335120 |
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma |
RECRUITING | |
| NCT07259070 |
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma |
RECRUITING | PHASE1/PHASE2 |
| NCT07162012 |
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma |
RECRUITING | EARLY_PHASE1 |
| NCT07070648 |
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET |
RECRUITING | |
| NCT07041827 |
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma |
COMPLETED |
